JP2023536634A5 - - Google Patents

Info

Publication number
JP2023536634A5
JP2023536634A5 JP2023507678A JP2023507678A JP2023536634A5 JP 2023536634 A5 JP2023536634 A5 JP 2023536634A5 JP 2023507678 A JP2023507678 A JP 2023507678A JP 2023507678 A JP2023507678 A JP 2023507678A JP 2023536634 A5 JP2023536634 A5 JP 2023536634A5
Authority
JP
Japan
Prior art keywords
optionally substituted
membered
alkyl
group
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507678A
Other languages
English (en)
Japanese (ja)
Other versions
JP7893801B2 (ja
JP2023536634A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044692 external-priority patent/WO2022031939A1/en
Publication of JP2023536634A publication Critical patent/JP2023536634A/ja
Publication of JP2023536634A5 publication Critical patent/JP2023536634A5/ja
Application granted granted Critical
Publication of JP7893801B2 publication Critical patent/JP7893801B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507678A 2020-08-07 2021-08-05 自己免疫疾患および癌の処置のための小分子 Active JP7893801B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063062670P 2020-08-07 2020-08-07
US63/062,670 2020-08-07
PCT/US2021/044692 WO2022031939A1 (en) 2020-08-07 2021-08-05 Small molecules for the treatment of autoimmune diseases and cancer

Publications (3)

Publication Number Publication Date
JP2023536634A JP2023536634A (ja) 2023-08-28
JP2023536634A5 true JP2023536634A5 (enExample) 2024-08-15
JP7893801B2 JP7893801B2 (ja) 2026-07-22

Family

ID=80118531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507678A Active JP7893801B2 (ja) 2020-08-07 2021-08-05 自己免疫疾患および癌の処置のための小分子

Country Status (9)

Country Link
US (2) US11485728B2 (enExample)
EP (1) EP4192826A4 (enExample)
JP (1) JP7893801B2 (enExample)
KR (1) KR20230065261A (enExample)
CN (1) CN116323587A (enExample)
AU (1) AU2021320254A1 (enExample)
CA (1) CA3188260A1 (enExample)
IL (1) IL300351A (enExample)
WO (1) WO2022031939A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020214537A1 (en) 2019-04-15 2020-10-22 Tosk, Inc. Modulators of ras gtpase
KR102695540B1 (ko) * 2020-09-21 2024-08-14 재단법인 아산사회복지재단 퀴나졸린-2,4-다이아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US12180220B2 (en) 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
US20220112178A1 (en) * 2020-10-14 2022-04-14 Tosk, Inc. Small Molecule Modulators of RAS GTPase
JP2024511012A (ja) * 2021-03-24 2024-03-12 アトス セラピューティクス，インコーポレイテッド キナーゼ関連疾患の処置のための小分子
CN114522185A (zh) * 2022-04-12 2022-05-24 南京大学 拟杆菌Bacteroides caecimuris在制备治疗肝损伤药物中的应用
EP4268823A1 (en) * 2022-04-25 2023-11-01 Universitätsklinikum Hamburg-Eppendorf Compound for treating neuroinflammation
WO2025006391A1 (en) * 2023-06-26 2025-01-02 Athos Therapeutics, Inc. Small molecules for the treatment of autoimmune disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
CA2649995A1 (en) * 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
WO2009053694A1 (en) * 2007-10-24 2009-04-30 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
JP2014231475A (ja) 2011-08-25 2014-12-11 田辺三菱製薬株式会社 新規化合物及びそのｐｄｅ１０阻害薬としての使用
US20150259649A1 (en) * 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
CN105473581B (zh) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) * 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
WO2016172332A1 (en) 2015-04-22 2016-10-27 The University Of North Carolina At Chapel Hill A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility
US10407423B2 (en) 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
WO2017201199A1 (en) 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018089835A1 (en) * 2016-11-10 2018-05-17 La Jolla Institute For Allergy And Immunology A pro-inflammatory role for adenosine uptake and metabolism
CA3047579A1 (en) * 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
WO2019006322A1 (en) * 2017-06-30 2019-01-03 The University Of North Carolina At Chapel Hill HETEROCROMATINE GENE REPRESSION INHIBITORS
US11944624B2 (en) * 2017-07-06 2024-04-02 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
WO2020132409A1 (en) * 2018-12-20 2020-06-25 Trustees Of Boston University Stk19 inhibitors for treatment of cancer

Similar Documents

Publication Publication Date Title
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN109789146B (zh) 趋化因子受体调节剂及其用途
EP4045037B1 (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP5542133B2 (ja) ピラゾロ−キナゾリン
ES2638850T3 (es) Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
JP2010523722A5 (enExample)
US9850229B2 (en) Compounds and compositions as protein kinase inhibitors
RU2008110941A (ru) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2008526824A5 (enExample)
JP2009507036A5 (enExample)
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
RU2002107203A (ru) Производные N-гетероциклических соединений в качестве ингибиторов синтазы оксида азота (nos)
JP2012506381A5 (enExample)
JP2009542721A5 (enExample)
JP2005527628A5 (enExample)
RU2009145270A (ru) Производные 1, 3-дигидроимидазол-2-тиона в качестве ингибиторов дофамин-бета-гидроксилазы
JP2013514980A5 (enExample)
JP2006528161A (ja) ヒスタミンのアンタゴニストとしてのピペリジンのイミダゾール誘導体
JP2022533958A5 (enExample)
US20210188836A1 (en) 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
JP2005513020A5 (enExample)
RU2006134022A (ru) Производные индазола и содержащие их фармацевтические композиции
RU2005122615A (ru) Соединения n-(индолэтил)циклоамина
RU2007116987A (ru) Новые соединения
RU2005138371A (ru) Производные бензимидазола, композиции, содержащие их, их получение и их применение